Olema Pharmaceuticals
OLMA
69 hedge funds and large institutions have $1.05B invested in Olema Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 14 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
5.45% more ownership
Funds ownership: 87.73% → 93.17% (+5.4%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
7% less funds holding
Funds holding: 74 → 69 (-5)
10% less capital invested
Capital invested by funds: $1.16B → $1.05B (-$111M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.7M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$13.6M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$9.95M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.36M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$9.98M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.7M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.47M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.15M |
OLMA Hedge Fund Activity: Q2 2021 in Review
69 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q2 2021, worth a combined $1.05B — down 9.6% from $1.16B a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of OLMA and 9 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 30 added.
The largest buyer was Vanguard Group, adding an estimated $43.7M. The largest seller was Wellington Management Group, cutting an estimated $11.4M.
- 69 institutional investors held Olema Pharmaceuticals (OLMA) as of Q2 2021, down from 74 in Q1 2021.
- Funds reported $1.05B of Olema Pharmaceuticals stock for Q2 2021, down 9.6% quarter-over-quarter.
- 9 funds opened new Olema Pharmaceuticals positions in Q2 2021 and 14 closed out, a net change of -5 holders.
- The largest Olema Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $43.7M added.
- The largest Olema Pharmaceuticals seller in Q2 2021 was Wellington Management Group, an estimated $11.4M sold.
Based on aggregated 13F filings for Q2 2021.